This bill reauthorizes and updates the American Battlefield Protection Program through 2036, extending funding for battlefield preservation grants. It increases the maximum grant percentage for battlefield interpretation projects from 50% to 75% and sets $2 million annually for battlefield restoration grants through 2036. The bill also requires the National Park Service to study French and Indian War (1754-1763) and Mexican-American War (1846-1848) sites across the U.S., assessing their significance, threats, and preservation options. These studies must involve state governors, tribal governments, local officials, and historic preservation groups, with a final report due to Congress within two years of funding. The program directly affects federal, state, tribal, and local entities managing historic battlefields.
The Whale CHARTS Act of 2026 establishes a program to protect migratory whales and other large cetaceans through improved mapping, monitoring, and mitigation measures. It requires the creation of detailed, high-resolution maps of whale habitats, including calving grounds and migration routes, which will be integrated into vessel navigation systems to prevent collisions. The bill authorizes $8 million annually through 2030 for mapping, surveys, and a $10 million grant program to fund new detection technologies that reduce harmful interactions between whales and ocean users. It also mandates regular reporting to Congress on the program's effectiveness and progress in filling knowledge gaps about whale habitats.
HR 6529, the Protecting Families from AI Data Center Energy Costs Act, mandates the Federal Energy Regulatory Commission (FERC) to hold a technical conference within 90 days of enactment. The conference will include AI data centers, utilities, and ratepayer advocates to develop strategies protecting residential and small commercial customers from rising energy costs caused by large energy users. FERC must then submit a report with recommendations to Congress within 180 days. This procedural bill directly affects households and small businesses facing potential rate increases due to AI data center energy demands.
HR 6213, the Heat Workforce Standards Act of 2025, prohibits the U.S. Department of Labor from finalizing, implementing, or enforcing OSHA's proposed "Heat Injury and Illness Prevention" standard (published August 30, 2024). This bill directly blocks the specific regulatory proposal targeting heat safety in both outdoor and indoor work settings. It does not create new requirements or affect workers; it solely prevents the implementation of the existing OSHA proposal. The bill is procedural, focusing on halting a regulatory action rather than establishing new policy.
The NIH IMPROVE Act (HR 6238) establishes a new NIH research initiative focused on improving maternal health outcomes in the U.S. It directly affects pregnant and postpartum women, particularly those in communities experiencing health disparities linked to higher maternal mortality and severe maternal morbidity. The bill authorizes $73.4 million annually (2026-2031) for NIH to fund research targeting preventable causes of maternal deaths, reduce health disparities, and evaluate community-based interventions. Key provisions require NIH to advance evidence-based solutions through grants and studies on biological, behavioral, and regional factors affecting maternal health before, during, and after pregnancy.
This bill reauthorizes funding for the C.W. Bill Young Cell Transplantation Program, setting $31 million for fiscal year 2025 and $33 million annually for fiscal years 2027-2031. It also extends the deadline for the national cord blood inventory program from 2026 to 2031. The legislation directly affects stem cell research programs and cord blood banks by maintaining federal funding levels and prolonging the inventory program’s timeline. These provisions ensure continuity for existing research infrastructure and blood bank operations without introducing new policy changes.
This bill reauthorizes federal programs focused on preventing and responding to tick-borne diseases through 2026-2030, extending existing efforts beyond their previous expiration. It updates the National Strategy for Vector-Borne Diseases to emphasize identifying, reporting, preventing, and responding to these illnesses. The bill modifies two sections of the Public Health Service Act to continue funding for health departments working on vector-borne disease control. It directly affects public health programs and state/local health departments managing tick-borne disease prevention and response.
HR 4123, the FIT Procurement Act, modernizes federal information and communications technology (ICT) procurement by requiring new training for federal acquisition staff and streamlining processes to boost small business participation. The bill mandates a cross-functional ICT training program covering cloud computing, AI, cybersecurity, and commercial tech adoption, with learning objectives focused on outcome-based contracting and reducing waste. It increases simplified acquisition thresholds ($250,000 to $500,000) and micro-purchase limits ($10,000 to $25,000) to reduce administrative barriers. The Act also directs the Comptroller General to assess small business participation in federal tech contracts and requires agencies to eliminate unnecessary procedural hurdles for small businesses. These changes directly affect federal procurement staff, small businesses competing for contracts, and executive agencies managing ICT acquisitions.
The AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.
This bill establishes the INCLUDE Project at the National Institutes of Health (NIH) to advance research on Down syndrome and related health conditions. It requires NIH to fund high-risk studies on trisomy 21, support inclusive clinical trials for people with Down syndrome across all ages, and investigate co-occurring conditions like Alzheimer’s disease and autoimmunity. The law mandates NIH coordination across its institutes, consultation with patient advocates, and biennial reports to Congress detailing funded research and its real-world applications. The project directly affects individuals with Down syndrome, their families, and medical researchers, aiming to improve diagnosis, treatment, and quality of life through targeted scientific efforts.
This bill reauthorizes the National Earthquake Hazards Reduction Program through fiscal year 2030, providing $83.4 million annually with $30 million each year dedicated to completing the Advanced National Seismic System. It expands the program to include Tribal governments, updates standards to cover building design, evaluation, and post-earthquake recovery (such as minimizing downtime for critical infrastructure), and requires better coordination between federal agencies like the USGS, Federal Communications Commission, and FEMA for earthquake early warnings. The bill mandates that early warning alerts be broadcast in the predominant languages of affected regions and includes new provisions for tsunami response coordination and data sharing.
HR 2821, the FDA Modernization Act 3.0, requires the FDA to update regulatory language within one year of enactment. It directs the agency to replace all references to "animal tests" with "nonclinical tests" in 22 specific sections of the Code of Federal Regulations related to drug development and approval processes. The bill also adds a definition for "nonclinical test" into relevant FDA regulations to align with prior legislative changes. This update applies directly to pharmaceutical manufacturers and FDA reviewers who follow these regulatory guidelines during drug development. The changes aim to modernize terminology without altering current testing requirements.
